Dean J. Naylor

Corporate Officer/Principal presso The University of Queensland

Consumer Services

Health Technology

Profilo

Dean J.
Naylor is currently a Principal at The University of Queensland.
Prior to this, he was a Principal at the University of Adelaide and Head-Intellectual Property Development at CBio Ltd.

Posizioni attive di Dean J. Naylor

Società	Posizione	Inizio
The University of Queensland	Corporate Officer/Principal	-

Tutte le posizioni attive di Dean J. Naylor

Precedenti posizioni note di Dean J. Naylor

Società	Posizione	Fine
University of Adelaide	Corporate Officer/Principal	-
CBio Ltd. CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Dean J. Naylor

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Dean J. Naylor

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
CBio Ltd. CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia.	Health Technology